Glycovax-002(Glycovax-002) - _专利_临床

概要

基本信息

药物类型

疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域-

在研适应症-

非在研适应症-

原研机构

Glycovax Pharma, Inc.初创企业

在研机构

Seppic S.A.

Avance Clinical Pty Ltd.初创企业

Glycovax Pharma, Inc.初创企业

+ [1]

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Glycovax-002 相关的临床试验

NCT05799651 / Active, not recruiting临床1期

A Randomised, Double-Blind, Dose-Escalation Phase I Study in Healthy Adults to Assess the Safety, Tolerability and Immunogenicity of Glycovax-002, a Novel Vaccine Candidate Against COVID-19

Glycovax Pharma has developed a glycoconjugate vaccine candidate called Glycovax-002 to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the origin of COVID-19.
The aim of the study is to assess the safety, reactogenicity and immunogenicity of Glycovax-002 in humans. The study is a phase I, placebo-controlled, dose-escalation study conducted in 36 healthy females and males aged between 18 and 55 years old. The vaccine will be administered three times with a two-week time interval between each dose.
Dose escalation is conducted in three steps. At each step, 9 participants receiving the vaccine will be randomized with 3 participants receiving placebo (normal saline). Progression to next step is conditional to a DSMB's approval.

开始日期2023-04-28

申办/合作机构

Glycovax Pharma, Inc.初创企业

[+4]

100 项与 Glycovax-002 相关的临床结果

登录后查看更多信息

100 项与 Glycovax-002 相关的转化医学

登录后查看更多信息

100 项与 Glycovax-002 相关的专利（医药）

登录后查看更多信息

100 项与 Glycovax-002 相关的药物交易

登录后查看更多信息